This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Pymepharco Joint Stock Company
Pymepharco Joint Stock Company, commonly referred to as Pymepharco, is a prominent player in the pharmaceutical industry, headquartered in Vietnam. Established in 1997, the company has made significant strides in the production and distribution of high-quality pharmaceutical products across various regions, including the southern provinces of Vietnam. Specialising in the manufacture of generic medicines, Pymepharco is renowned for its commitment to quality and innovation. The company offers a diverse range of products, including prescription medications and over-the-counter solutions, which are distinguished by their efficacy and safety. With a strong market position, Pymepharco has achieved notable milestones, including certifications from international health authorities, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Pymepharco Joint Stock Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pymepharco Joint Stock Company's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pymepharco Joint Stock Company, headquartered in Vietnam, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of STADA Arzneimittel Aktiengesellschaft, which influences its climate commitments and initiatives. While no direct emissions data is available, Pymepharco's climate strategy is likely aligned with the broader sustainability goals set by its parent company, STADA Arzneimittel Aktiengesellschaft. This includes initiatives related to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from STADA at a level 2 relationship. However, specific reduction targets or achievements have not been disclosed for Pymepharco. As a subsidiary, Pymepharco may benefit from STADA's established climate commitments, which could include efforts to reduce emissions across various scopes, although detailed information on these initiatives is not provided. The company is expected to adhere to industry-standard climate terminology and practices, reflecting a commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 31,639,700 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,032,800 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pymepharco Joint Stock Company is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
